Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.
Authors
Einat K. Brenner (ORCID: https://orcid.org/0000-0002-0172-8277)
Katherine J. Bangen (ORCID: https://orcid.org/0000-0002-1363-3179)
Alexandra J. Weigand (ORCID: https://orcid.org/0000-0002-7931-1383)
Maria Bordyug
Lauren C. Edwards
Kelsey R. Thomas (ORCID: https://orcid.org/0000-0003-4277-8876)
Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.
Einat K. Brenner, Katherine J. Bangen, Alexandra J. Weigand, Maria Bordyug et al.
Citations
1 citations
Journal
Neuropsychology
Topics
Alzheimer's disease research and treatments
Field-Weighted Citation Impact (FWCI)
1.16
article
Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.
Einat K. Brenner, Katherine J. Bangen, Alexandra J. Weigand, Maria Bordyug, Lauren C. Edwards, Kelsey R. Thomas, Amanda Gonzalez, Uriel Urias
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
NeuropsychologyVol. 39(3)
Institutions
San Diego State University (US), University of California San Diego (US)
Funders
U.S. Department of Defense, Alzheimer's Association, National Institutes of Health